HealthCare Global Enterprises (HCG) Q4 24/25 earnings summary

Executive summary

• Achieved strong operational and financial performance in FY25, with significant revenue and EBITDA growth driven by core oncology centers, expansion initiatives, and digital transformation.

• Welcomed new investors, with KKR set to acquire up to 54% of the company at Rs. 445 per share, supporting a long-term vision and future growth, subject to regulatory approvals.

• Continued leadership in cancer care with a pan-India presence, advanced technology, and a robust hub-and-spoke model, commanding market leadership in 16 of 18 cities.

• Focused investments in early cancer detection, precision medicine, and next-generation diagnostic capabilities.

• Audited standalone and consolidated financial results for FY25 were approved with an unmodified audit opinion.

Financial highlights

• FY25 consolidated revenue grew 16% year-over-year to Rs 22,228 mn; Q4FY25 revenue up 18% to Rs 5,851 mn.

• Adjusted EBITDA for FY25 rose 17% to Rs 3,963 mn (17.8% margin); Q4FY25 adjusted EBITDA was Rs 1,070 mn (18.3% margin).

• FY25 consolidated net profit was Rs. 4,085 lakhs, up from Rs. 2,714 lakhs in FY24; standalone net profit was Rs. 353 lakhs, down from Rs. 3,280 lakhs.

• Digital channel revenues grew 42% year-over-year in Q4FY25, with campaign revenues up 106%.

• ARPOB increased 5.4% to Rs 44,041; established centers at Rs 42,595 (+2.5%), emerging centers at Rs 66,755 (+12.5%).

Outlook and guidance

• Targeting over 900 new operational beds in the next three years, including new centers in Bangalore and Ahmedabad.

• Margin improvement and ROCE accretion expected through advanced technology, cost optimization, and ramp-up of emerging centers.

• Anticipating 7%-8% ARPOB growth in FY26, driven by higher-value metro centers.

• Effective tax rate expected to be around 30% for FY26.

• No forward-looking financial guidance was provided in statutory filings.